Members of the TRiNDS team, including its board of directors, have a long-term commitment to translational research and drug development in the neuromuscular community. They represent key opinion leaders from the bench to the bedside. The TRiNDS personnel and Board have played central roles in the design and management of the CINRG Duchenne Natural History Study (DNHS), the largest longitudinal controlled study of patients with Duchenne across the age range.
TRiNDS was formed by colleagues at several academic centers that are part of the CINRG network. The TRiNDS team builds on the strong leadership skills developed by the CINRG consortium. It is focused on providing efficient services to pharmaceutical and biotechnology industries as well as academic investigators. TRiNDS combines international disease expertise with regulatory agency compliant data and project management solutions as well as study design, biostatistical analyses and interpretation.
Through approved access to completed and ongoing natural histories in Duchenne, Becker, and facioscapulohumeral muscular dystrophy TRiNDS can works with customers on their clinical trial programs. Summary data can assist with trial planning and sample size calculations, study endpoint selection, individual patient matching analyses, and more.
TRiNDS has established a group of partners and clients.